Sorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutation

Academic Article

Abstract

  • Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML). FLT3 inhibitors such as sorafenib have been shown to have a potential role in treating relapsed or refractory AML with FLT3 mutations. In the present report, the use of sorafenib in combination with cytarabine and idarubicin resulted in disease control for 7 months in an older patient with relapsed FLT3-positive AML. This case report and the existing literature indicate that sorafenib has disease activity against relapsed AML with the FLT3-ITD mutation in older patients. Larger multicenter studies should be conducted to confirm these findings, which have the potential to improve outcomes in this high-risk AML subgroup.
  • Authors

    Digital Object Identifier (doi)

    Pubmed Id

  • 223381
  • Author List

  • Giri S; Hamdeh S; Bhatt VR; Schwarz JK
  • Start Page

  • 508
  • End Page

  • 514
  • Volume

  • 13
  • Issue

  • 5